Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial.
Philip D HomeRaymond L H LamWendy L CarofanoGregory T GolmRoy EldorMichael F CrutchlowMichael C MarcosJulio RosenstockPriscilla A HollanderBaptist GallwitzPublished in: Diabetes, obesity & metabolism (2018)
Mk-Gla and Sa-Gla exhibited similar efficacy and safety over 52 weeks in people with T1DM. ClinicalTrials.gov: NCT02059161.